Thelansis

  B-Cell Acute lymphoblastic leukemia (ALL) is a type of blood cancer in which many abnormal, immature lymphocytes known as blasts begin to multiply in the bone marrow. Lymphocytes are white blood cells that play a role in the immune response. B-ALL is characterized by the expression of various B–cell-specific antigens, which often include PAX-5, CD19, CD20, CD22, CD24, and CD79a. B-cell ALL is primarily a childhood disease, with approximately 75% of cases being children aged <6 years, however, the majority of the B-Cell ALL occurs in the <15 years of age; also, the peak of the incidence is seen in people around 40 years. Approximately 20% to 30% of adult acute lymphoblastic leukemias (ALLs) and 5% of pediatric ALLs harbor the Ph-chromosome. This genetic alteration confers a poor prognosis, as defined by shorter remission duration and shorter survival, and higher rates of resistance to standard chemotherapy. CNS involvement is more common in relapsed adult patients. In childr...